Sanjay Chanda, PhD

AN2 Therapeutics, Inc.

Poster(s):

• (2144) A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics (PK) of Oral Epetraborole Tablets in Adult Subjects with Varying Degrees of Renal Function
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET

• (2556) A Phase 1, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics (PK), Safety, and Tolerability of Epetraborole Tablets and the Impact of Alcohol Dehydrogenase (ADH) Genotype on the PK of Epetraborole and Metabolite M3 in Healthy Japanese Adult Subjects
  Saturday, October 14, 2023

  12:15 PM – 1:30 PM US ET